Table 2 Characteristics of the clinical trials included in the systematic review with meta-analysis
First author name | Country | Gender | Year | Sample size | Treatment | Mean age | Dose | Measure | Method of BC assay | Pre-DAS-28 | Post-DAS-28 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Marcora [29] | France | M/F | 2006 | 24 | Group 1: etanercept Group 2: MTX | NI | Group 1: 50 mg/week Group 2: 7.5~15 mg/week | Lean mass | DEXA | Group 1: 6.1 ± 0.7 Group 2: 5.8 ± 1.1 | Group 1: t3.2 ± 1.5 Group 2: 3.1 ± 1.5 |
Engvall [30] | Sweden | M/F | 2010 | 40 | Group 1: MTX + SSZ + HCQ Group 2: infliximab + MTX | Group 1: 59.5 Group 2: 56.0 | Group 1: 20 mg/week MTX + 2000 mg/day SSZ + 400 mg/day HCQ Group 2: 20 mg/week MTX + 3 mg/kg infliximab (weeks 0, 2, 6 and every 8 weeks) | Lean mass App. lean mass | DEXA | Group 1: 4.3 Group 2: 4.8 | NI |